Framework for the Development of Data-Driven Mamdani-Type Fuzzy Clinical Decision Support Systems.

Diagnostics (Basel)

Facultad de Ingeniería, Universidad Francisco de Paula Santander, Cúcuta, Santander, 540001, Colombia.

Published: May 2019

Clinical decision support systems (CDSS) have been designed, implemented, and validated to help clinicians and practitioners for decision-making about diagnosing some diseases. Within the CDSSs, we can find Fuzzy inference systems. For the reasons above, the objective of this study was to design, to implement, and to validate a methodology for developing data-driven Mamdani-type fuzzy clinical decision support systems using clusters and pivot tables. For validating the proposed methodology, we applied our algorithms on five public datasets including Wisconsin, Coimbra breast cancer, wart treatment (Immunotherapy and cryotherapy), and caesarian section, and compared them with other related works (Literature). The results show that the Kappa Statistics and accuracies were close to 1.0% and 100%, respectively for each output variable, which shows better accuracy than some literature results. The proposed framework could be considered as a deep learning technique because it is composed of various processing layers to learn representations of data with multiple levels of abstraction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628283PMC
http://dx.doi.org/10.3390/diagnostics9020052DOI Listing

Publication Analysis

Top Keywords

clinical decision
12
decision support
12
support systems
12
data-driven mamdani-type
8
mamdani-type fuzzy
8
fuzzy clinical
8
framework development
4
development data-driven
4
systems
4
systems clinical
4

Similar Publications

Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.

Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.

View Article and Find Full Text PDF

Introduction: This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally once daily for 14 days on platelet reactivity with respect to aspirin reaction units (ARUs) and P2Y reaction units (PRUs).

Methods: Twenty-two patients with stable coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) with daily maintenance aspirin and clopidogrel were recruited.

View Article and Find Full Text PDF

Introduction: Dolutegravir (DTG) + lamivudine (3TC) demonstrated high rates of virologic suppression (VS) and low rates of virologic failure (VF), discontinuation, and drug resistance in randomized trials. Real-world evidence can support treatment effectiveness, safety, and tolerability in clinical practice and aid in treatment decisions.

Methods: A systematic literature review (SLR) was conducted to identify studies using DTG + 3TC (January 2013-March 2024).

View Article and Find Full Text PDF

Background: Groove pancreatitis (GP) is a form of pancreatitis that affects the pancreaticoduodenal groove area, which lies between the head of the pancreas, the second part of the duodenum and the distal bile duct, presenting as abdominal pain and gastric outlet obstruction. In this study, we present the clinical and radiological characteristics of individuals diagnosed with groove pancreatitis at our center and discuss the use of a conservative treatment approach in managing GP.

Methods: The data of patients with groove pancreatitis treated at our center between January 2012 and December 2021 was analyzed.

View Article and Find Full Text PDF

Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults.

Drugs Aging

January 2025

Program for the Care and Study of the Aging Heart, Department of Medicine, Weill Cornell Medicine, 420 East 70th St, New York, NY, LH-36510063, USA.

There are several pharmacologic agents that have been touted as guideline-directed medical therapy for heart failure with preserved ejection fraction (HFpEF). However, it is important to recognize that older adults with HFpEF also contend with an increased risk for adverse effects from medications due to age-related changes in pharmacokinetics and pharmacodynamics of medications, as well as the concurrence of geriatric conditions such as polypharmacy and frailty. With this review, we discuss the underlying evidence for the benefits of various treatments in HFpEF and incorporate key considerations for older adults, a subpopulation that may be at higher risk for adverse drug events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!